iShares US Pharmaceuticals ETF
194 hedge funds and large institutions have $658M invested in iShares US Pharmaceuticals ETF in 2026 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 64 increasing their positions, 37 reducing their positions, and 13 closing their positions.
162% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 13
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
73% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 37
20% more capital invested
Capital invested by funds: $550M → $658M (+$108M)
9% more funds holding
Funds holding: 178 → 194 (+16)
1.26% more ownership
Funds ownership: 64.85% → 66.11% (+1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Aptus Capital Advisors
Fairhope,
Alabama
|
+$25.1M |
| 2 |
MSCM
McElhenny Sheffield Capital Management
Dallas,
Texas
|
+$17.7M |
| 3 |
JP Morgan Chase
New York
|
+$14.3M |
| 4 |
IWS
Insight Wealth Strategies
San Ramon,
California
|
+$10.4M |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$8.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWM
Accurate Wealth Management
Wesley Chapel,
Florida
|
-$6.37M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
-$5.1M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$4.35M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3.56M |
| 5 |
BCV
Banque Cantonale Vaudoise
Lausanne,
Switzerland
|
-$2.08M |
IHE Hedge Fund Activity: Q1 2026 in Review
194 of the 8,180 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2026, worth a combined $658M — up 20% from $550M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new IHE positions and 13 closed out — a net gain of 21 holders — while 64 added to existing stakes and 37 trimmed.
The largest buyer was Aptus Capital Advisors, adding an estimated $25.1M. The largest seller was Accurate Wealth Management, exiting entirely with an estimated $6.37M sold.
- 194 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2026, up from 178 in Q4 2025.
- Funds reported $658M of iShares US Pharmaceuticals ETF stock for Q1 2026, up 20% quarter-over-quarter.
- 34 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2026 and 13 closed out, a net change of +21 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q1 2026 was Aptus Capital Advisors, an estimated $25.1M added.
- The largest iShares US Pharmaceuticals ETF seller in Q1 2026 was Accurate Wealth Management, an estimated $6.37M sold.
Based on aggregated 13F filings for Q1 2026.